Brokerage firm Nuvama expects Kilpest India to sustain healthy growth in the molecular diagnostics business, led by product launches, acquisition of new customers, and geographical expansion. The brokerage has a “buy” rating on the stock with a price target of Rs 1,184. This implies an upside potential of 57% from the current levels.